Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents
- PMID: 34228985
- PMCID: PMC8253718
- DOI: 10.1016/j.jpeds.2021.06.083
Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents
Abstract
Reports have emerged of myocarditis and pericarditis predominantly after the second dose of the coronavirus disease messenger ribonucleic acid vaccine. We describe 13 patients aged 12-17 years who presented with chest pain within 1 week after their second dose of the Pfizer vaccine and were found to have elevated serum troponin levels and evidence of myopericarditis.
Keywords: COVID-19 vaccine; myocarditis.
Copyright © 2021 Elsevier Inc. All rights reserved.
Figures
Comment in
-
Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents.J Pediatr. 2021 Nov;238:5. doi: 10.1016/j.jpeds.2021.07.057. Epub 2021 Jul 29. J Pediatr. 2021. PMID: 34332972 Free PMC article. No abstract available.
References
-
- Hinton D.M. FDA Emergency use authorization for Pfizer-BioNTech COVID-19 vaccine [Letter] 2021. https://www.fda.gov/media/144412/download Accessed June 16, 2021.
-
- Washington State Department of Health COVID-19 data dashboard 2021. https://www.doh.wa.gov/Emergencies/COVID19/DataDashboard Accessed June 21, 2021.
-
- Marshall M., Ferguson I.D., Lewis P., Jaggi P., Gagliardo C., Collins J.S., et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021 e2021052478. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
